Meeting
2018 Gastrointestinal Cancers Symposium
Clinical benefit of maintenance therapy for patients with advanced biliary tract cancer without progression on first-line gemcitabine plus cisplatin.
Authors
Jaewon Hyung
Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of (South)
Jaewon Hyung , Changhoon Yoo , Kyu-Pyo Kim , Bum Jun Kim , Jae Ho Jeong , Heung-Moon Chang , Baek-Yeol Ryoo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 36, 2018 (suppl 4S; abstr 357)
DOI
10.1200/JCO.2018.36.4_suppl.357
Abstract #
357
Poster Bd #
G18
Abstract Disclosures
Similar Posters
Poster
2016 Gastrointestinal Cancers Symposium
Long-term responders to palliative chemotherapy for advanced biliary tract cancer.
First Author: Mark Doherty
Poster
2014 Gastrointestinal Cancers Symposium
Prognostic factors in advanced biliary tract cancer treated with first-line chemotherapy with cisplatin and gemcitabine.
First Author: Renata D'Alpino Peixoto
Poster
2023 ASCO Annual Meeting
Phase 2 multicenter trial of rucaparib and nivolumab as maintenance therapy following first-line platinum-based chemotherapy in patients with advanced biliary tract cancer (BTC): BilT-02.
First Author: Vaibhav Sahai
Poster
2016 Gastrointestinal Cancers Symposium
Second-line chemotherapy (CTx) outcomes in advanced biliary cancers (ABC): A retrospective multicenter analysis.
First Author: Maeve Aine Lowery